ClinicalTrials.gg
CompletedNCT00243503Updated Jul 22, 2011Results posted

Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer

A Phase 2 interventional study of SU011248/Trastuzumab in Breast Neoplasms, sponsored by Pfizer. Completed at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-22.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies testing sunitinib in Breast Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. Sunitinib · Breast Neoplasms.

Enrollment
15th of 29
60 · median 60
Started
2006
with 5 others
Phase 2
13 of 29
none open now
Registered
3rd of 29
by date
Lead sponsor
14 of 29
Pfizer

Among the 29 studies testing sunitinib in Breast Neoplasms, this one is the 15th largest by enrollment, is one of 6 that started in 2006, is one of 13 in phase 2, and was the 3rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 29 studies testing sunitinib in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sunitinib

Sunitinib: first FDA approval 2006 (SUTENT), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing sunitinib in Breast Neoplasms, or all of them as a file.
02

Study summary

The current study is to evaluate: Overall response rate for the combination of trastuzumab and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and tolerability of the combination; measure duration of tumor control and survival; assess patient reported outcomes; assess PK in combination with trastuzumab and compare efficacy and safety.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

Keywords

  • Breast Cancer Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of breast cancer with evidence of 1) unresectable, locally recurrent, or 2) disease.
  • positive disease (3+ by immunohistochemistry [IHC] or FISH-positive)
  • Candidate for treatment with trastuzumab. Prior treatment with trastuzumab and or/ lapatinib in the , adjuvant or metastatic disease setting is permitted. Treatment with hormone therapy in the adjuvant and/or advanced disease setting is permitted.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with >1 regimen of cytotoxic therapy in the advanced disease setting. chemotherapy is permitted
  • Prior exposure to trastuzumab if the patient had developed severe reactions.
  • Prior treatment on a SU11248 clinical trial.
  • Uncontrolled .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    A

    Drug: SU011248/Trastuzumab

Interventions

  • DrugSU011248/Trastuzumab

    Drug pages: SunitinibStudies of SunitinibSunitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Confirmed Objective Disease Response

    Objective disease response =participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target and non-target lesions. A PR was defined as a \> = 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions associated to a non-progressive disease response for the non target lesions.

    Time frame: From start of treatment through 18 months

Secondary outcomes

  1. Duration of Response (DR)

    Time from the first documentation of objective tumor response (CR or PR) that was subsequently confirmed to the first documentation of objective tumor progression or death due to any cause. If tumor progression data included more than 1 date, the first date was used. DR was calculated as (the end date for DR minus first CR or PR that was subsequently confirmed +1) divided by 7.

    Time frame: From start of treatment through 18 months

  2. Percentage of Participants With Clinical Benefit

    Percent of participants with confirmed CR, PR or stable disease (SD) for at least 24 weeks on study according to RECIST.CR was defined as disappearance of all target and non-target lesions.PR was defined as \>=30% decrease in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions associated to non-progressive disease response for non target lesions.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started.

    Time frame: From start of treatment through 18 months

  3. Progression Free Survival (PFS)

    Time from first dose of study treatment to first documentation of objective tumor progression, or to death on-study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. PFS was calculated as (first event date minus first dose date +1) divided by 7.

    Time frame: From start of treatment through 18 months

  4. Time to Progression (TTP)

    Time from first dose of study treatment to first documentation of objective tumor progression. If tumor progression data included more than 1 date, the first date was used. TTP was calculated as (first event date minus first dose date +1) divided by 7.

    Time frame: From start of treatment through 18 months

  5. Overall Survival (OS)

    Time from first dose of study treatment to first documentation of death due to any cause. OS was calculated as (date of death minus first dose date +1) divided by 7 \* 4.33.

    Time frame: From start of study treatment until death or 2 years from first study treatment

  6. Probability of Survival at One Year

    One- year survival probability was estimated using the Kaplan-Meier method.

    Time frame: From start of study treatment until death or 2 years from first study treatment

  7. EORTC QLQ-C30

    EORTC QLQ-C30 scales consist of 30 questions: functional (physical/role/cognitive/emotional/ social), symptom (fatigue/nausea/vomiting/pain), global health/QOL, cancer symptom (dyspnea/insomnia/appetite loss/constipation/diarrhea). Feelings in past week: response range: not at all to very much, global/QOL range: very poor to excellent. Scales/single-items averaged, score 0 to 100. Higher functional/global=better functioning and symptom=greater degree of symptoms.

    Time frame: From start of treatment through 18 months

  8. EORTC QLQ (BR23)

    BR23: consisted of 23 questions which measured disease related symptoms of dry mouth, eye pain, hair loss, hot flushes, attractiveness, future health, sexual activity, arm/shoulder pain, breast pain, swollen breast, and skin problems on the breast. Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.

    Time frame: From start of treatment through 18 months

  9. Dose-corrected Trough Plasma Concentrations (Ctrough) of Sunitinib

    Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.

    Time frame: Predose on Day 1 of Cycle 3 and 5

  10. Dose-corrected Ctrough of SU-012662 (Sunitinib's Metabolite)

    Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.

    Time frame: Predose on Day 1 of Cycle 3 and 5

  11. Dose-corrected Ctrough of Total Drug (Sunitinib + SU-012662)

    Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.

    Time frame: Predose on Day 1 of Cycle 3 and 5

07

Results

Posted May 19, 2010

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab + Sunitinib
Started60
Completed2
Not completed58
Withdrew: Adverse event11
Withdrew: Withdrawal by subject1
Withdrew: Lack of efficacy44
Withdrew: Death1
Withdrew: Other1

Outcome measures

PrimaryPercentage of Participants With Overall Confirmed Objective Disease Response

Objective disease response =participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target and non-target lesions. A PR was defined as a \> = 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions associated to a non-progressive disease response for the non target lesions.

Time frame:
From start of treatment through 18 months
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Confirmed Objective Disease Response
percentage of participantsTrastuzumab + Sunitinib
Percentage of Participants With Overall Confirmed Objective Disease Response36.8 (24.4 to 50.7)
SecondaryDuration of Response (DR)

Time from the first documentation of objective tumor response (CR or PR) that was subsequently confirmed to the first documentation of objective tumor progression or death due to any cause. If tumor progression data included more than 1 date, the first date was used. DR was calculated as (the end date for DR minus first CR or PR that was subsequently confirmed +1) divided by 7.

Time frame:
From start of treatment through 18 months
Reported as:
Median · weeks
Duration of Response (DR)
weeksTrastuzumab + Sunitinib
Duration of Response (DR)25.6 (22.4 to 32.9)
SecondaryPercentage of Participants With Clinical Benefit

Percent of participants with confirmed CR, PR or stable disease (SD) for at least 24 weeks on study according to RECIST.CR was defined as disappearance of all target and non-target lesions.PR was defined as \>=30% decrease in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions associated to non-progressive disease response for non target lesions.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started.

Time frame:
From start of treatment through 18 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Benefit
Percentage of ParticipantsTrastuzumab + Sunitinib
Percentage of Participants With Clinical Benefit56.1 (42.4 to 69.3)
SecondaryProgression Free Survival (PFS)

Time from first dose of study treatment to first documentation of objective tumor progression, or to death on-study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. PFS was calculated as (first event date minus first dose date +1) divided by 7.

Time frame:
From start of treatment through 18 months
Reported as:
Median · Weeks
Progression Free Survival (PFS)
WeeksTrastuzumab + Sunitinib
Progression Free Survival (PFS)28.0 (24.1 to 31.3)
SecondaryTime to Progression (TTP)

Time from first dose of study treatment to first documentation of objective tumor progression. If tumor progression data included more than 1 date, the first date was used. TTP was calculated as (first event date minus first dose date +1) divided by 7.

Time frame:
From start of treatment through 18 months
Reported as:
Median · weeks
Time to Progression (TTP)
weeksTrastuzumab + Sunitinib
Time to Progression (TTP)26.0 (23.3 to 31.1)
SecondaryOverall Survival (OS)

Time from first dose of study treatment to first documentation of death due to any cause. OS was calculated as (date of death minus first dose date +1) divided by 7 \* 4.33.

Time frame:
From start of study treatment until death or 2 years from first study treatment
Reported as:
Median · months
Overall Survival (OS)
monthsTrastuzumab + Sunitinib
Overall Survival (OS)NA (NA to NA)
SecondaryProbability of Survival at One Year

One- year survival probability was estimated using the Kaplan-Meier method.

Time frame:
From start of study treatment until death or 2 years from first study treatment
Reported as:
Number · percentage of 1-year survival
Probability of Survival at One Year
percentage of 1-year survivalTrastuzumab + Sunitinib
Probability of Survival at One Year91.2 (80.2 to 96.3)
SecondaryEORTC QLQ-C30

EORTC QLQ-C30 scales consist of 30 questions: functional (physical/role/cognitive/emotional/ social), symptom (fatigue/nausea/vomiting/pain), global health/QOL, cancer symptom (dyspnea/insomnia/appetite loss/constipation/diarrhea). Feelings in past week: response range: not at all to very much, global/QOL range: very poor to excellent. Scales/single-items averaged, score 0 to 100. Higher functional/global=better functioning and symptom=greater degree of symptoms.

Time frame:
From start of treatment through 18 months
Reported as:
Mean · scores on a scale
EORTC QLQ-C30
scores on a scaleTrastuzumab + Sunitinib
Function Score: Global health (n=28)56.0 ± 21.4
Function Score: Physical function (n=28)75.2 ± 16.8
Function Score: Role function (n=28)60.1 ± 28.8
Function Score: Cognitive function (n=28)84.5 ± 21.7
Function Score: Emotional function (n=28)66.1 ± 27.5
Function Score: Social function (n=28)66.7 ± 28.3
Symptom Score: Fatigue (n=28)45.0 ± 25.3
Symptom Score: Pain (n=28)36.9 ± 25.8
Symptom Score: Nausea/vomiting (n=28)6.5 ± 10.5
Symptom Score: Dyspnea (n=28)26.2 ± 30.6
Symptom Score: Loss of appetite (n=28)20.2 ± 24.6
Symptom Score: Insomnia (n=28)29.8 ± 27.7
Symptom Score: Constipation (n=27)14.8 ± 26.7
Symptom Score: Diarrhea (n=27)32.1 ± 32.7
Symptom Score: Financial difficulty (n=28)17.9 ± 29.4
SecondaryEORTC QLQ (BR23)

BR23: consisted of 23 questions which measured disease related symptoms of dry mouth, eye pain, hair loss, hot flushes, attractiveness, future health, sexual activity, arm/shoulder pain, breast pain, swollen breast, and skin problems on the breast. Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.

Time frame:
From start of treatment through 18 months
Reported as:
Mean · scores on a scale
EORTC QLQ (BR23)
scores on a scaleTrastuzumab + Sunitinib
Function Score : Body image (n=27)76.4 ± 29.5
Function Score: Sexual function (n=24)14.6 ± 16.5
Function Score: Sexual enjoyment (n=10)33.3 ± 15.7
Others :Future health perspective (n=27)45.7 ± 34.8
Symptom Score: systemic therapy side effects(n=27)21.7 ± 15.8
Symptom Score: Breast (n=27)19.4 ± 23.6
Symptom Score: Arm (n=27)21.0 ± 23.9
Others :Upset of hair loss (n=6)44.4 ± 27.2
SecondaryDose-corrected Trough Plasma Concentrations (Ctrough) of Sunitinib

Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.

Time frame:
Predose on Day 1 of Cycle 3 and 5
Reported as:
Mean · nanograms (ng)/milliliter (mL)
Dose-corrected Trough Plasma Concentrations (Ctrough) of Sunitinib
nanograms (ng)/milliliter (mL)Trastuzumab + Sunitinib
Day 1 (Cycle 3)53.5 ± 27.6
Day 1 (Cycle 5)55.0 ± 24.8
SecondaryDose-corrected Ctrough of SU-012662 (Sunitinib's Metabolite)

Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.

Time frame:
Predose on Day 1 of Cycle 3 and 5
Reported as:
Mean · ng/mL
Dose-corrected Ctrough of SU-012662 (Sunitinib's Metabolite)
ng/mLTrastuzumab + Sunitinib
Day 1 (Cycle 3)26.7 ± 14.4
Day 1 (Cycle 5)24.7 ± 12.5
SecondaryDose-corrected Ctrough of Total Drug (Sunitinib + SU-012662)

Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.

Time frame:
Predose on Day 1 of Cycle 3 and 5
Reported as:
Mean · ng/mL
Dose-corrected Ctrough of Total Drug (Sunitinib + SU-012662)
ng/mLTrastuzumab + Sunitinib
Day 1 (Cycle 3)80.2 ± 39.9
Day 1 (Cycle 5)79.7 ± 36.3

Adverse events

Collected over From time of informed consent signing (SAEs) or first study treatment (AEs) through 18 months and including 28 calendar days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab + Sunitinib—25/60 (41.7%)59/60 (98.3%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventTrastuzumab + Sunitinib
ThrombocytopeniaBlood and lymphatic system disorders3/60
Febrile neutropeniaBlood and lymphatic system disorders2/60
PancreatitisGastrointestinal disorders2/60
VomitingGastrointestinal disorders2/60
AstheniaGeneral disorders2/60
EpistaxisRespiratory, thoracic and mediastinal disorders2/60
HypertensionVascular disorders2/60
AnaemiaBlood and lymphatic system disorders1/60
Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders1/60
Cardiac failureCardiac disorders1/60
Most frequent other events
Showing 10 of 70
Most frequent other events
EventTrastuzumab + Sunitinib
DiarrhoeaGastrointestinal disorders36/60
AstheniaGeneral disorders29/60
DysgeusiaNervous system disorders27/60
HypertensionVascular disorders25/60
VomitingGastrointestinal disorders21/60
Mucosal inflammationGeneral disorders21/60
DyspepsiaGastrointestinal disorders20/60
NauseaGastrointestinal disorders20/60
FatigueGeneral disorders19/60
HeadacheNervous system disorders18/60

Baseline characteristics

Age Continuous
Age Continuous(Years)Trastuzumab + Sunitinib
Mean55.1 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab + Sunitinib
Female60
Male0
EORTC QLQ-C30
EORTC QLQ-C30(scores on a scale)Trastuzumab + Sunitinib
Function Score: Global health (n=48)66.8 ± 26.8
Function Score: Physical function (n=49)79.5 ± 21.3
Function Score: Role function (n=49)76.2 ± 30.0
Function Score: Cognitive function (n=49)82.0 ± 25.6
Function Score: Emotional function (n=49)62.8 ± 26.4
Function Score: Social function (n=49)75.5 ± 29.9
Symptom Score: Fatigue (n=49)35.6 ± 27.6
Symptom Score: Pain (n=49)38.8 ± 33.7
Symptom Score: Nausea/vomiting (n=49)7.1 ± 18.0
Symptom Score: Dyspnea (n=48)22.9 ± 28.5
Symptom Score: Loss of appetite (n=49)14.3 ± 28.1
Symptom Score: Insomnia (n=49)35.4 ± 31.5
Symptom Score: Constipation (n=48)18.1 ± 32.9
Symptom Score: Diarrhea (n=49)6.8 ± 15.2
Symptom Score: Financial difficulty (n=48)15.3 ± 28.3
EORTC QLQ Breast Cancer Module (BR23)
EORTC QLQ Breast Cancer Module (BR23)(scores on a scale)Trastuzumab + Sunitinib
Function Score : Body image (n=46)77.2 ± 25.4
Function Score: Sexual function (n=44)21.6 ± 24.5
Function Score: Sexual enjoyment (n=15)53.3 ± 21.1
Symptom Score: Arm (n=48)23.8 ± 25.3
Symptom Score: Breast (n=47)25.9 ± 27.5
Symptom Score: systemic therapy side effects(n=48)17.2 ± 17.4
Others :Upset of hair loss (n=6)50.0 ± 27.9
Others :Future health perspective (n=48)39.6 ± 32.0
08

Study locations

27 sites
  • Pfizer Investigational Site
    Montgomery, Alabama 36106, United States
  • Pfizer Investigational Site
    Newark, Delaware 19713, United States
  • Pfizer Investigational Site
    Newark, Delaware 19718-6001, United States
  • Pfizer Investigational Site
    Wilmington, Delaware 19899, United States
  • Pfizer Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • Pfizer Investigational Site
    Harvey, Illinois 60426, United States
  • Pfizer Investigational Site
    Tinley Park, Illinois 60477, United States
  • Pfizer Investigational Site
    Munster, Indiana 46321, United States
  • Pfizer Investigational Site
    Lafayette, Louisiana 70503, United States
  • Pfizer Investigational Site
    New Iberia, Louisiana 70563, United States
  • Pfizer Investigational Site
    Corinth, Mississippi 38834, United States
  • Pfizer Investigational Site
    Southaven, Mississippi 38671, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89135, United States
  • Pfizer Investigational Site
    New York, New York 10021, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38104, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38120, United States
  • Pfizer Investigational Site
    Ottignies, 1340, Belgium
  • Pfizer Investigational Site
    Wilrijk, 2610, Belgium
  • Pfizer Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • Pfizer Investigational Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3G 1A4, Canada
  • Pfizer Investigational Site
    Besancon, 25030, France
  • Pfizer Investigational Site
    Lyon, 69373, France
  • Pfizer Investigational Site
    Saint Cloud, 92210, France
  • Pfizer Investigational Site
    Barcelona, 08003, Spain
  • Pfizer Investigational Site
    Madrid, 28040, Spain
  • Pfizer Investigational Site
    Valencia, 46010, Spain
09

References and documents

Publications

  • Bachelot T, Garcia-Saenz JA, Verma S, Gutierrez M, Pivot X, Kozloff MF, Prady C, Huang X, Khosravan R, Wang Z, Cesari R, Tassell V, Kern KA, Blay JY, Lluch A. Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer. 2014 Mar 7;14:166. doi: 10.1186/1471-2407-14-166. PubMed 24606768 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Apr 2009 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2005
First posted
Oct 24, 2005
Start
Feb 2006
Primary completionActual
Apr 2009
CompletionActual
Jul 2010
Results first posted
May 19, 2010
Last update
Jul 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00243503
Lead sponsor
Pfizer
First posted
Oct 24, 2005
Start date
Feb 2006
Primary completion
Apr 2009
Completion
Jul 2010
Results posted
May 19, 2010
Last update
Jul 22, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sunitinib · Trastuzumab

Start the discussion